Profile data is unavailable for this security.
About the company
Onconetix, Inc. is a commercial stage biotechnology company. It is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has Entadfi, a Food and Drug Administration approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Entadfi is a once-daily, oral treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Proclarix is a next generation protein-based blood test that can be done with the same sample as a patient’s regular PSA test. Proteomedix is seeking to develop diagnostic, prognostic, and predictive tools to enable cancer management at all stages of disease progression.
- Revenue in USD (TTM)1.46m
- Net income in USD-53.12m
- Incorporated2018
- Employees12.00
- LocationOnconetix Inc201 E. Fifth Street, Suite 1900CINCINNATI 45202United StatesUSA
- Phone+1 (513) 620-4101
- Fax+1 (845) 818-3588
- Websitehttps://onconetix.gcs-web.com/
More ▼
Mergers & acquisitions
| Acquired company | ONCO:NAQ since announced | Transaction value |
|---|---|---|
| ProteoMediX Ltd | -81.53% | -- |
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aytu Biopharma Inc | 81.00m | -15.84m | 10.88m | 99.00 | -- | 0.3814 | -- | 0.1344 | -2.86 | -2.86 | 14.63 | 4.64 | 0.6364 | 2.15 | 3.08 | 818,202.00 | -12.45 | -27.76 | -25.70 | -46.03 | 67.39 | 58.88 | -19.56 | -56.45 | 0.7916 | -0.0594 | 0.3531 | -- | -24.58 | 61.73 | 7.08 | -- | -- | -- |
| Bio Essence Corp | 593.21k | -1.02m | 11.59m | 12.00 | -- | -- | -- | 19.53 | -0.0278 | -0.0156 | 0.0158 | -0.0458 | 0.3305 | -- | 21.20 | -- | -57.09 | -46.10 | -- | -- | 25.05 | 33.89 | -172.74 | -111.21 | -- | -59.99 | 7.03 | -- | -11.27 | -10.94 | -52.03 | -- | -48.19 | -- |
| NDT Pharmaceuticals Inc | -100.00bn | -100.00bn | 12.59m | 1.00 | -- | 0.0703 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
| Immunoprecise Antibodies Ltd | 17.30m | -19.83m | 12.91m | 102.00 | -- | 0.518 | -- | 0.746 | -0.7492 | -0.7492 | 0.6615 | 0.8642 | 0.3546 | 6.12 | 6.16 | -- | -40.63 | -26.70 | -46.68 | -30.31 | 48.21 | 56.13 | -114.58 | -85.72 | 0.8189 | -134.72 | 0.3289 | -- | 18.65 | 17.54 | -2.32 | -- | 16.71 | -- |
| Talphera Inc | 398.00k | -13.70m | 15.12m | 15.00 | -- | 1.19 | -- | 38.00 | -0.6353 | -0.6323 | 0.0185 | 0.7491 | 0.0187 | -- | -- | 26,533.33 | -64.37 | -22.60 | -78.11 | -28.55 | -- | -- | -3,443.22 | -714.87 | -- | -- | 0.00 | -- | -- | -21.26 | -119.16 | -- | -34.33 | -- |
| Bright Green Corp | 0.00 | -9.92m | 15.33m | 5.00 | -- | 1.54 | -- | -- | -0.0538 | -0.0538 | 0.00 | 0.0519 | 0.00 | -- | -- | 0.00 | -47.48 | -- | -72.55 | -- | -- | -- | -- | -- | -- | -- | 0.0494 | -- | -- | -- | 52.54 | -- | -- | -- |
| Onconetix Inc | 1.46m | -53.12m | 16.42m | 12.00 | -- | -- | -- | 11.22 | -104.90 | -104.90 | 2.89 | 50.92 | 0.0328 | 3.45 | 5.30 | 121,979.20 | -119.09 | -- | -215.11 | -- | -57.21 | -- | -3,629.24 | -- | 0.091 | -11.87 | 0.2984 | -- | -- | -- | -176.78 | -- | -- | -- |
| Cumberland Pharmaceuticals, Inc. | 37.79m | -10.38m | 16.81m | 91.00 | -- | 0.6414 | -- | 0.445 | -0.7328 | -0.7328 | 2.67 | 1.87 | 0.4501 | 0.8643 | 3.17 | 415,225.80 | -12.35 | -7.03 | -17.75 | -9.52 | 82.58 | 79.95 | -27.45 | -17.64 | 1.26 | -38.85 | 0.382 | -- | -5.85 | 6.15 | -12.73 | -- | -36.17 | -- |
| TherapeuticsMD Inc | 996.00k | -4.83m | 17.53m | 1.00 | -- | 0.6335 | -- | 17.60 | -0.4348 | -0.5538 | 0.0889 | 2.40 | 0.0212 | -- | 0.5048 | 996,000.00 | -10.31 | -53.35 | -13.13 | -111.61 | 45.08 | 86.67 | -485.34 | -236.57 | -- | -- | 0.00 | -- | -98.14 | -39.53 | -816.85 | -- | -- | -- |
| Marinus Pharmaceuticals Inc | 30.26m | -149.24m | 18.44m | 165.00 | -- | -- | -- | 0.6092 | -2.66 | -2.66 | 0.5391 | -0.8614 | 0.21 | 0.7508 | 6.98 | 183,412.10 | -103.54 | -49.64 | -131.60 | -57.76 | 90.64 | -- | -493.14 | -518.96 | 2.15 | -11.80 | 6.10 | -- | 21.63 | -- | -613.59 | -- | 7.47 | -- |
| Cara Therapeutics Inc | 11.00m | -111.08m | 18.70m | 55.00 | -- | 1.61 | -- | 1.70 | -2.04 | -2.04 | 0.2017 | 0.2115 | 0.1063 | 1.10 | 2.10 | 199,927.30 | -107.38 | -35.76 | -132.61 | -40.82 | 74.66 | -- | -1,010.20 | -162.10 | 4.48 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
| DH Enchantment Inc | 100.00 | -173.19k | 19.54m | 1.00 | -- | -- | -- | 195,396.80 | -0.0002 | -0.0002 | 0.00 | -0.0012 | 0.0438 | 0.1493 | -- | 100.00 | -7,579.43 | -- | -- | -- | 0.00 | -- | -173,190.00 | -- | 0.0029 | -14.85 | -- | -- | -95.43 | -- | 59.53 | -- | -- | -- |
| Cyclo Therapeutics Inc | 1.13m | -20.74m | 20.37m | 8.00 | -- | -- | -- | 17.99 | -0.9104 | -0.9104 | 0.0474 | -0.1785 | 0.242 | 0.4002 | 13.16 | 141,553.80 | -443.08 | -132.22 | -- | -215.17 | 91.56 | 90.37 | -1,831.29 | -1,114.04 | 0.4283 | -- | -- | -- | -21.76 | 1.25 | -29.81 | -- | -3.95 | -- |
| China Health Industries Holdings, Inc. | 95.95k | -1.36m | 21.30m | 32.00 | -- | -- | -- | 221.99 | -0.0208 | -0.0208 | 0.0015 | -0.0366 | 0.0037 | 0.5035 | 20.57 | 2,998.44 | -5.18 | 3.04 | -6.89 | 3.66 | -5.34 | 69.55 | -1,419.49 | 28.61 | 0.0377 | -- | 1.76 | -- | 41,225.93 | -55.72 | -15.49 | -- | -- | -- |
| Gelteq Ltd | 0.00 | -1.56m | 21.80m | -- | -- | 1.52 | -- | -- | -0.1627 | -0.1627 | 0.00 | 1.52 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.38 | -32.41 | 0.0605 | -- | -- | -- | -72.77 | -- | -- | -- |
Data as of Nov 12 2024. Currency figures normalised to Onconetix Inc's reporting currency: US Dollar USD
0.83%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| American Money Management Corp.as of 30 Jun 2024 | 36.02k | 0.43% |
| Cetera Investment Advisers LLCas of 30 Jun 2024 | 8.00k | 0.10% |
| Z�rcher Kantonalbank (Investment Management)as of 30 Sep 2024 | 7.65k | 0.09% |
| Bank of America, NA (Private Banking)as of 30 Jun 2024 | 3.13k | 0.04% |
| G1 Execution Services LLCas of 30 Jun 2024 | 2.84k | 0.03% |
| HRT Financial LP (US)as of 30 Jun 2024 | 2.62k | 0.03% |
| Fifth Third Bank, NA (Investment Management)as of 30 Sep 2024 | 2.40k | 0.03% |
| Geode Capital Management LLCas of 30 Jun 2024 | 2.38k | 0.03% |
| Jane Street Capital LLCas of 30 Jun 2024 | 2.18k | 0.03% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.84k | 0.02% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
